Challenges in developing new tuberculosis vaccines
Introduction: Tuberculosis (TB) is a preventable and curable disease caused by Mycobacterium tuberculosis (M.tuberculosis).In 2022, TB was the second leading cause of death worldwide due to a single infectious agent, after COVID-19.Brazil is among the 30 countries with the highest TB burden.The Bacillus Calmette-Gurin (BCG) vaccine is the only licensed vaccine for TB.While it provides protection against severe childhood TB, its effectiveness in preventing adult pulmonary TB is limited, underscoring the need for a more effective vaccine.Objectives: This study aims to explore the challenges in developing new TB vaccines.
Authors
- Clarice Monteiro Vianna (ORCID: https://orcid.org/0009-0002-6424-3266)
- Danieli Lazarini de Barros
- Maria de Lourdes de Sousa Maia (ORCID: https://orcid.org/0000-0003-4223-9151)
- Ernani Paulino do Lago
- Bruno Bezerra da Silva (ORCID: https://orcid.org/0000-0002-9881-201X)
- Celia Marques
- Ewerton Alves Portela dos Santos
- E. N. A. Santos
- Gabriela Sadigurschi
- Maria Kuschni
Publication Details
- Published
- 2025-01-01
- DOI
- https://doi.org/10.35259/isi.2025_70240
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00